B群脑膜炎球菌外膜囊泡疫苗抗淋病效果:一项回顾性观察研究
该研究在纽约市和费城对16-23岁人群进行回顾性观察,将淋病和衣原体感染监测记录与免疫登记记录链接,评估MenB-4C疫苗对淋病的保护效果。结果显示,完整接种系列抗淋病效力为40%(95%CI 23-53),部分接种系列效力为26%(95%CI 12-37),MenB-4C接种与淋病患病率降低相关。
要点
- 完整MenB-4C接种系列抗淋病效力40%(95%CI 23-53)。
- 部分MenB-4C接种系列抗淋病效力26%(95%CI 12-37)。
- MenB-4C可能对淋病奈瑟菌提供交叉保护。
核心结论
- MenB-4C疫苗接种与淋病患病率降低相关。
- MenB-4C可能对淋病奈瑟菌提供交叉保护。
- 开发有效的淋球菌疫苗可能是可行的,对淋病预防和控制有意义。
研究设计与样本
- 回顾性观察研究,利用2016年至2018年纽约市和费城的性传播感染监测记录,识别16-23岁人群中实验室确诊的淋病和衣原体感染。
- 将淋病和衣原体病例记录与免疫登记记录链接,确定感染时MenB-4C接种状态:完整接种(两剂MenB-4C,间隔30-180天)、部分接种(单剂MenB-4C疫苗)或无接种(B群脑膜炎球菌疫苗未接种)。
- 使用对数二项回归和广义估计方程解释同一患者多次感染的相关性,计算调整患病率比(APR)和95%CI。
- 描述性分析使用个体水平数据,回归分析使用感染水平数据。
- 共识别109737名个体中的167706例感染(18099例淋球菌感染、124876例衣原体感染、24731例淋球菌和衣原体混合感染),其中7692人接种疫苗。
主要发现
- 接种疫苗的7692人中,4032人(52.4%)接种一剂,3596人(46.7%)接种两剂,64人(<1.0%)接种至少三剂。
- 与无接种相比,完整接种系列对淋病有保护作用(APR 0.60,95%CI 0.47-0.77;p<0.0001)。
- 与无接种相比,部分接种系列对淋病有保护作用(APR 0.74,95%CI 0.63-0.88;p=0.0012)。
- 完整MenB-4C接种系列抗淋病效力为40%(95%CI 23-53)。
- 部分MenB-4C接种系列抗淋病效力为26%(95%CI 12-37)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Declining antimicrobial susceptibility to current gonorrhoea antibiotic treatment and inadequate treatment options have raised the possibility of untreatable gonorrhoea. New prevention approaches, such as vaccination, are needed. Outer membrane vesicle meningococcal serogroup B vaccines might be protective against gonorrhoea. We evaluated the effectiveness of a serogroup B meningococcal outer membrane vesicle vaccine (MenB-4C) against gonorrhoea in individuals aged 16-23 years in two US cities. METHODS: We identified laboratory-confirmed gonorrhoea and chlamydia infections among individuals aged 16-23 years from sexually transmitted infection surveillance records in New York City and Philadelphia from 2016 to 2018. We linked gonorrhoea and chlamydia case records to immunisation registry records to determine MenB-4C vaccination status at infection, defined as complete vaccination (two MenB-4C doses administered 30-180 days apart), partial vaccination (single MenB-4C vaccine dose), or no vaccination (serogroup B meningococcal vaccine naive). Using log-binomial regression with generalised estimating equations to account for correlations between multiple infections per patient, we calculated adjusted prevalence ratios (APR) and 95% CIs to determine if vaccination was protective against gonorrhoea. We used individual-level data for descriptive analyses and infection-level data for regression analyses. FINDINGS: Between Jan 1, 2016, and Dec 31, 2018, we identified 167 706 infections (18 099 gonococcal infections, 124 876 chlamydial infections, and 24 731 gonococcal and chlamydial co-infections) among 109 737 individuals linked to the immunisation registries. 7692 individuals were vaccinated, of whom 4032 (52·4%) had received one dose, 3596 (46·7%) two doses, and 64 (<1·0%) at least three doses. Compared with no vaccination, complete vaccination series (APR 0·60, 95% CI 0·47-0·77; p<0·0001) and partial vaccination series (0·74, 0·63-0·88; p=0·0012) were protective against gonorrhoea. Complete MenB-4C vaccination series was 40% (95% CI 23-53) effective against gonorrhoea and partial MenB-4C vaccination series was 26% (12-37) effective. INTERPRETATION: MenB-4C vaccination was associated with a reduced gonorrhoea prevalence. MenB-4C could offer cross-protection against Neisseria gonorrhoeae. Development of an effective gonococcal vaccine might be feasible with implications for gonorrhoea prevention and control. FUNDING: None.
引用
- Abara WE, Bernstein KT, Lewis FMT, et al. Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis. 2022. PMID: 35427490. doi:10.1016/S1473-3099(21)00812-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。